Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
E Protalix BioTherapeutics Pipeline Progress
Article By:
Terry Chrisomalis
Wednesday, July 29, 2020 9:54 AM EDT
Protalix Biotherapeutics (PLX) offers great potential in the coming months as its lead candidate, PLX-102 - a therapy for Fabry disease, is edging closer to the finish line.
These Are Some Of The Coronavirus Vaccine Candidates
Article By:
ValueWalk
Monday, May 25, 2020 6:28 PM EDT
As far as which coronavirus vaccine candidates will be tested first, researchers will look at production capacity and the amount of immune response generated in early trials and animal studies.
Sanofi To Sell Investment In Regeneron, Says Will Not Impact Collaboration
Article By:
The Fly
Monday, May 25, 2020 3:22 PM EDT
Sanofi announced its intent to sell its equity investment in Regeneron Pharmaceuticals through a registered public offering. The registered offering and share repurchase will have no impact on the ongoing collaboration between the two.
Week In Review: How Trump's Policies Moved Stocks - Saturday, May 23
Article By:
The Fly
Saturday, May 23, 2020 6:13 PM EDT
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration.
Protalix BioTherapeutics Pipeline Progress
My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.